Medulloblastoma

Clinical Oncology

Volumn 25, Issue 1, 2013, Pages 36-45

  Bartlett, F ^a   Kortmann, R ^b   Saran, F ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Chemotherapy; Clinical trials; Medulloblastoma; Paediatrics; Radiotherapy

Indexed keywords

APC PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; HYDROXYUREA; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PROCARBAZINE; VINCRISTINE;

ABDUCENS NERVE PARALYSIS; ANASTOMOSIS; ARTICLE; ASEPTIC MENINGITIS; ATAXIA; BASAL CELL NEVUS SYNDROME; BRAIN HEMATOMA; BRAIN VENTRICLE PERITONEUM SHUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; CRANIECTOMY; CRANIOSPINAL IRRADIATION; CRANIOTOMY; EVENT FREE SURVIVAL; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEDLINE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OPHTHALMOPLEGIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON THERAPY; TROCHLEAR NERVE PALSY; VOMITING;

BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; HUMANS; MEDULLOBLASTOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 84871449144     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.09.008     Document Type: Article

References (72)

1. Farwell J.R., Dohrmann G.J., Flannery J.T. MB in childhood: an epidemiological study. J Neurosurg 1984, 61(4):657-664.
2. Roberts R.O., Lynch C.F., Jones M.P., et al. MB: a population-based study of 532 cases. J Neuropathol Exp Neurol 1991, 50(2):134-144.
3. Alston R.D., Newton R., Kelsey A., et al. Childhood MB in Northwest England 1954 to 1997: incidence and survival. Dev Med Child Neurol 2003, 45(5):308-314.
4. Park T.S., Hoffman H.J., Hendrick E.B., et al. MB: clinical presentation and management. Experience at the Hospital For Sick Children, Toronto, 1950-1980. J Neurosurg 1983, 58(4):543-552.
5. Provias J.P., Becker L.E. Cellular and molecular pathology of medulloblastoma. J Neurooncol 1996, 29(1):35-43.
6. Cowan R., Hoban P., Kelsey A., et al. The gene for the naevoid basal cell carcinoma syndrome acts as a tumour suppressor gene in MB. Br J Cancer 1997, 76(2):141-145.
7. Wechsler-Reya R.J., Scott M.P. Control of neuronal precursor proliferation in the cerebellum by Sonic Hedgehog. Neuron 1999, 22(1):103-114.
8. Thompson M.C., Fuller C., Hogg T.L., et al. Genomics identifies MB subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006, 24(12):1924-1930.
9. Pizem J., Cört A., Zadravec-Zaletel L., et al. Survivin is a negative prognostic marker in MB. Neuropathol Appl Neurobiol 2005, 31(4):422-428.
10. Fangusaro J.R., Jiang Y., Holloway M.P. Survivin, Survivin-2B, and Survivin-deltaEx3 expression in MB: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005, 92(2):359-365.
11. Fan X., Mikolaenko I., Elhassan I., et al. Notch1 and Notch2 have opposite effects on embryonal brain tumour growth. Cancer Res 2004, 64(21):7787-7793.
12. Hallahan A.R., Pritchard J.I., Hansen S., et al. The SmoA1 mouse model reveals that Notch signalling is critical for the growth and survival of Sonic Hedgehog-induce MB. Cancer Res 2004, 64(21):7794-7800.
13. Herms J., Neidt I., Lüscher B., et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 2000, 89(5):395-402.
14. Eberhart C.G., Kratz J., Wang Y., et al. Histopathological and molecular prognostic markers in MB: C-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004, 63(5):441-449.
15. Bühren J., Christoph A.H., Buslei R., et al. Expression of the neurotrophin receptor p75NTR in MB is correlated with distinct histological and clinical features: evidence for a MB subtype derived from the external granule cell layer. J Neuropathol Exp Neurol 2000, 59(3):229-240.
16. Nelson M., Diebler C., Forbes W.S. Paediatric MB: atypical CT features at presentation in the SIOP II trial. Neuroradiology 1991, 33(2):140-142.
17. Meyers S.P., Kemp S.S., Tan R.W. MR imaging features of MB. Am J Roentgenol 1992, 158(4):859-865.
18. Chang C.H., Housepian E.M., Herbert C. An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas. Radiology 1969, 93(6):1351-1359.
19. Zeltzer P.M., Boyett J.M., Finlay J.L., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999, 17(3):832-845.
20. Gilbertson R.J., Clifford S.C., MacMeekin W., et al. Expression of the ErbB-Neuregulin signalling network during human cerebellar development: implications for the biology of MB. Cancer Res 1998, 58(17):3932-3941.
21. Grotzer M.A., von Hoff K., von Bueren A.O., et al. Which clinical and biological tumour markers proved predictive in the postoperative multicenter HIT'91 - implications for investigating childhood MB. Klin Padiatr 2007, 219(6):312-317.
22. Rutkowski S., von Bueren A., von Hoff K., et al. Prognostic relevance of clinical and biological risk factors in childhood MB: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res 2007, 13(9):2651-2657.
23. Rogers H.A., Miller S., Lowe J., et al. An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). Br J Cancer 2009, 100(8):1292-1302.
24. Grundy R.G., Wilne S.H., Robinson K.J., et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer 2009, [Epub ahead of print].
25. Rutkowski S., Gerber N.U., von Hoff K., et al. Treatment of early childhood MB by postoperative chemotherapy and deferred radiotherapy. Neuro Oncol 2009, 11(2):201-210.
26. Bailey P., Cushing H. MB cerebelli: a common type of midcerebellar glioma of childhood. Arch Neurol Psych 1925, 14:192-223.
27. Kurpad S.N., Cohen A.R. Posterior fossa craniotomy: an alternative to craniectomy. Pediatr Neurosurg 1999, 31(1):54-57.
28. Gnanalingham K.K., Lafuente J., Thompson D., et al. Surgical procedures for posterior fossa tumors in children: does craniotomy lead to fewer complications than craniectomy?. J Neurosurg 2002, 97(4):821-826.
29. Bhatia R., Tahir M., Chandler C.L. The management of hydrocephalus in children with posterior fossa tumours: the role of pre-resectional endoscopic third ventriculostomy. Pediatr Neurosurg 2009, 45(3):186-191.
30. Sutton L.N., Phillips P.C., Molloy P.T. Surgical management of medulloblastoma. J Neurooncol 1996, 29(1):9-21.
31. Robertson P.L., Muraszko K.M., Holmes E.J., et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg 2006, 105(6 Suppl.):444-451.
32. Korah M.P., Esiashvili N., Mazewski C.M., et al. Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma. Int J Radiat Oncol Biol Phys 2009, [Epub ahead of print].
33. del Charco J.O., Bolek T.W., McCollough W.M., et al. Medulloblastoma: time-dose relationship based on a 30-year review. Int J Radiat Oncol Biol Phys 1998, 42(1):147-154.
34. Taylor R.E., Bailey C.C., Robinson K.J., et al. Impact of radiotherapy parameters on outcome in the International Society Of Pediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 MB. Int J Radiat Oncol Biol Phys 2004, 58(4):1184-1193.
35. Gandola L., Massimino M., Cefalo G., et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic MB. J Clin Oncol 2009, 27(4):566-571.
36. Dhall G., Grodman H., Ji L., et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the " Head Start" I and II protocols. Pediatr Blood Cancer 2008, 50(6):1169-1175.
37. Geyer J.R., Zeltzer P.M., Boyett J.M., et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 1994, 12(8):1607-1615.
38. Duffner P.K., Horowitz M.E., Krischer J.P., et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumours. N Engl J Med 1993, 328(24):1725-1731.
39. Rotkowski S., Bode U., Deinlein F., et al. Treatment of early childhood MB by postoperative chemotherapy alone. N Engl J Med 2005, 352(10):978-986.
40. Grill J., Sainte-Rose C., Jouvet A., et al. Treatment of MB with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005, 6(8):573-580.
41. Ris M.D., Packer R., Goldwein J. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for MB: a Children's Cancer Group study. J Clin Oncol 2001, 19(15):3470-3476.
42. Mulhern R.K., Kepner J.L., Thomas P.R., et al. Neuropsychologic functioning of survivors of childhood MB randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group Study. J Clin Oncol 1998, 16(5):1723-1728.
43. Heikens J., Miechels E.M., Behrendt H., et al. Long-term neuro-endocrine sequelae after treatment for childhood MB. Eur J Cancer 1998, 34(10):1592-1597.
44. Landier W. Hearing loss related to ototoxicity in children with cancer. J Pediatr Oncol Nurs 1998, 15(4):195-206.
45. Deutsch M., Thomas P.R., Krischer J. Results of a prospective randomized trial comparing standard neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage MB. A combined Children's Cancer Group-Pediatric Oncology Group study. Pediatr Neurosurg 1996, 24(4):167-176.
46. Bailey C.C., Gnekow A., Wellek S. Prospective randomised trial of chemotherapy given before radiotherapy in childhood MB. International Society of Pediatric Oncology (SIOP) and the (German) Society of Pediatric Oncology (GPO): SIOP II. Med Pediatr Oncol 1995, 25(3):166-178.
47. Packer R.J., Goldwein J., Stacy Nicholson H., et al. Treatment of children with MB with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study. J Clin Oncol 1999, 17(7):2127-2136.
48. Packer R.J., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk MB. J Clin Oncol 2006, 24(25):4202-4208.
49. Merchant T.E., Kun L.E., Krasin M.J. Multi-institution trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 2008, 70(3):782-787.
50. Tait D.M., Thornton-Jones H., Bloom H.J., et al. Adjuvant chemotherapy for MB: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990, 26(4):464-469.
51. Evans A.E., Jenkins R.D., Ortega J.A., et al. The treatment of MB. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990, 72(4):572-582.
52. Taylor R.E., Bailey C.C., Robinson K., et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study. J Clin Oncol 2003, 21(8):1581-1591.
53. Kortmann R.-D., Kühl J., Timmerman B., et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of MB in childhood: results of the German Prospective Randomized Trial HIT '91. Int J Radiat Oncol Biol Phys 2000, 46(2):269-279.
54. Von Hoff K., Hinkes B., Gerber N.U., et al. Long-term outcome and clinical prognostic factors in children with MB treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer 2009, 45:1209-1217.
55. Carrie C., Hoffstetter S., Gomez F., et al. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys 1999, 45(2):435-439.
56. Allen J., Donahue B., Mehta M., et al. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk MB/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). Int J Radiat Oncol Biol Phys 2009, 74(4):1006-1011.
57. Gajjar A., Chintagumpala M., Ashley D., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7(10):813-820.
58. Miralbell R., Fitzgerald T.J., Laurie F., et al. Radiotherapy in pediatric MB: quality assessment of Pediatric Oncology Group Trial 9031. Int J Radiat Oncol Biol Phys 2006, 64(5):1325-1330.
59. Parker W., Brodeur M., Roberge D., et al. Standard and nonstandard craniospinal radiotherapy using helical tomotherapy. Int J Radiat Oncol Biol Phys 2010, [Epub ahead of print].
60. Breen S.L., Kehagioglou P., Usher C., et al. A comparison of conventional, conformal and intensity-modulated coplanar radiotherapy plans for posterior fossa treatment. Br J Radiol 2004, 77(921):768-774.
61. Sharma D.S., Gupta T., Jalali R., et al. High-precision radiotherapy for craniospinal irradiation: evaluation of three-dimensional conformal radiotherapy, intensity modulated radiotherapy and helical tomotherapy. Br J Radiol 2009, 82(984):1000-1009.
62. St Clair W.H., Adams J.A., Bues M., et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004, 58(3):727-734.
63. Miralbell R., Lomax A., Russo M. Potential role of proton therapy in the treatment of pediatric MB/primitive neuro-ectodermal tumors: spinal theca irradiation. Int J Radiat Oncol Biol Phys 1997, 38(4):805-811.
64. Yuh G.E., Loredo L.N., Yonemoto L.T., et al. Reducing toxicity from craniospinal irradiation: using proton beams to treat MB in young children. Cancer J 2004, 10(6):386-390.
65. Miralbell R., Lomax A., Bortfield T., et al. Potential role of proton therapy in the treatment of pediatric MB/primitive neuroectodermal tumors: reduction of the supratentorial target volume. Int J Radiat Oncol Biol Phys 1997, 38(3):477-484.
66. Merchant T.E., Hua C.H., Shukla H., et al. Proton versus photon radiotherapy for common pediatric brain tumours: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 2008, 51(1):110-117.
67. Miralbell R., Lomax A., Cella L., et al. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002, 54(3):824-882.
68. Packer R.J., Sutton L.N., Goldwein J.W., et al. Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 1991, 74(3):433-440.
69. Grabenbauer G.G., Beck J.D., Erhardt J., et al. Postoperative radiotherapy of medulloblastoma: impact of radiation quality on treatment outcome. Am J Clin Oncol 1996, 19:73-77.
70. Gentet J.C., Bouffet E., Doz F., et al. Preirradiation chemotherapy including " eight drugs in 1 day" regimen and high-dose methotrexate in childhood medulloblastoma: results of the M7 French Cooperative Study. J Neurosurg 1995, 82(4):608-614.
71. Oyharcabal-Bourden V., Kalifa C., Gentet J.C., et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol 2005, 23(21):4726-4734.
72. Verlooy J., Mosseri V., Bracard S., et al. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer 2006, 42(17):3004-3014.